Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity
Victoria G. Klein, Adam G. Bond, Conner Craigon, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 24, pp. 18082-18101
Open Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

PROTACs: past, present and future
Ke Li, Craig M. Crews
Chemical Society Reviews (2022) Vol. 51, Iss. 12, pp. 5214-5236
Open Access | Times Cited: 425
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Claudia J. Diehl, Alessio Ciulli
Chemical Society Reviews (2022) Vol. 51, Iss. 19, pp. 8216-8257
Open Access | Times Cited: 124
Hydrogen-Bond Donors in Drug Design
Peter W. Kenny
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 21, pp. 14261-14275
Closed Access | Times Cited: 104
Degrader-antibody conjugates
Peter S. Dragovich
Chemical Society Reviews (2022) Vol. 51, Iss. 10, pp. 3886-3897
Closed Access | Times Cited: 84
Linker-Dependent Folding Rationalizes PROTAC Cell Permeability
Vasanthanathan Poongavanam, Yoseph Atilaw, Stephan Siegel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 13029-13040
Open Access | Times Cited: 76
Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders
Alexander Hanzl, Ryan Casement, Hana Imrichová, et al.
Nature Chemical Biology (2022) Vol. 19, Iss. 3, pp. 323-333
Open Access | Times Cited: 76
Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation
Ryan P. Wurz, Huan Rui, Ken Dellamaggiore, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 53
Advancing Strategies for Proteolysis-Targeting Chimera Design
Minglei Li, Ying Zhi, Bo Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2308-2329
Closed Access | Times Cited: 46
Accelerating Drug Discovery: Synthesis of Complex Chemotypes via Multicomponent Reactions
Melissa J. Buskes, Aaron Coffin, Dawn M. Troast, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 4, pp. 376-385
Open Access | Times Cited: 46
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 24
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D
Chuan Zhou, Zisheng Fan, Yuejiao Gu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1147-1167
Closed Access | Times Cited: 17
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5275-5304
Closed Access | Times Cited: 16
Emerging prodrug and nano-drug delivery strategies for the detection and elimination of senescent tumor cells
Tao Wang, Xianbao Shi, Xiaolong Xu, et al.
Biomaterials (2025), pp. 123129-123129
Closed Access | Times Cited: 2
Development of BromoTag: A “Bump-and-Hole”–PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins
Adam G. Bond, Conner Craigon, Kwok-Ho Chan, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 20, pp. 15477-15502
Open Access | Times Cited: 72
A bibliometric analysis of PROTAC from 2001 to 2021
Deping Li, Dongmin Yu, Yan Li, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114838-114838
Closed Access | Times Cited: 66
PROTAC degraders as chemical probes for studying target biology and target validation
Václav Nêmec, Martin P. Schwalm, Susanne Müller, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 18, pp. 7971-7993
Closed Access | Times Cited: 52
Degrader–Antibody Conjugates: Emerging New Modality
Ki Bum Hong, Hongchan An
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 140-148
Closed Access | Times Cited: 44
Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton’s Tyrosine Kinase for the Treatment of Lymphoma
Jingyu Zhang, Jinxin Che, Xiaomin Luo, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 9096-9125
Closed Access | Times Cited: 42
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Amide-to-ester substitution as a stable alternative to N-methylation for increasing membrane permeability in cyclic peptides
Yuki Hosono, S. Uchida, Moe Shinkai, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 34
Review and Chemoinformatic Analysis of Ferroptosis Modulators with a Focus on Natural Plant Products
Višnja Stepanić, Marta Kučerová-Chlupáčová
Molecules (2023) Vol. 28, Iss. 2, pp. 475-475
Open Access | Times Cited: 27
Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives
Jiarui Hu, Dan Zhang, Keyue Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115475-115475
Closed Access | Times Cited: 27
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers
Zehui Zhou, Guizhen Zhou, Chuan Zhou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 4197-4214
Closed Access | Times Cited: 24
Predictive Modeling of PROTAC Cell Permeability with Machine Learning
Vasanthanathan Poongavanam, Florian Kölling, Anja Giese, et al.
ACS Omega (2023) Vol. 8, Iss. 6, pp. 5901-5916
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top